Format

Send to

Choose Destination
PLoS One. 2016 Feb 17;11(2):e0148070. doi: 10.1371/journal.pone.0148070. eCollection 2016.

Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer.

Author information

1
Dept. of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
2
Medical Prognosis Institute, Hoersholm, Denmark.
3
Centre for Health Promotion and Rehabilitation, Faculty of Health Sciences, VIA University College, Aarhus, Denmark.
4
Dept. of Pathology, Aarhus University Hospital, Aarhus, Denmark.
5
Dept. of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Abstract

BACKGROUND:

miRNAs might be potentially useful biomarkers for prediction of response to chemotherapeutic agents, radiotherapy and survival. The aim of this retrospective study was to validate miRNA response predictors in a cohort of patients with gastrooesophageal cancer in order to predict overall survival (OS) and disease-specific survival (DSS).

MATERIAL AND METHODS:

The study population encompassed 53 patients treated with curative intend for loco-regional gastrooesophageal cancer. miRNA expression was quantified from pre-therapeutic and diagnostic, formalin-fixed, paraffin embedded tumour specimens using Affymetrix GeneChip miRNA 1.0 Array. Based on growth inhibition of the NCI60 panel in the presence of cisplatin, epirubicine and capecitabine, a miRNA based response predictor was developed. The Cox proportional hazards model was applied to assess the correlations of the response predictor with OS and DSS.

RESULTS:

A univariate analysis demonstrated a statistical significant improvement of OS for patients who had undergone surgical resection with prediction scores above the median prediction score (HR: 0.41 (95% CI: 0.17-0.96). Adjusting for surgery and stage, this predictor was identified to be independently associated with both OS (HR: 0.37 (95% CI: 0.16-0.87)) and DSS (HR: 0.32 (0.12-0.87)).

CONCLUSION:

The miRNA profile predictive for sensitivity to cisplatin, epirubicine and capecitabine was shown to be independently associated with OS and DSS in patients with gastrooesophageal cancer.

PMID:
26885979
PMCID:
PMC4757421
DOI:
10.1371/journal.pone.0148070
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center